FDA Review Criticizes Avandia Trial for Downplaying Reports of Injuries

GlaxoSmithKline received a major setback to its anti-type II diabetes drug Avandia this week. A researcher at the Food and Drug Administration released a scathing report that had strong criticism for a major clinical trial the company has been conducting into Avandia benefits. Read entire article

View post: 
FDA Review Criticizes Avandia Trial for Downplaying Reports of Injuries

This entry was posted on Tuesday, July 13th, 2010 at 6:23 pm and is filed under Accident Lawyer. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.